Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The impact of mutational clonality in predicting the response to immune checkpoint inhibitors in advanced urothelial cancer.

Scientific reports - 15 Sept 2023

Boll Lilian Marie, Perera-Bel Júlia, Rodriguez-Vida Alejo, Arpí Oriol, Rovira Ana, Juanpere Núria, Vázquez Montes de Oca Sergio, Hernández-Llodrà Silvia, Lloreta Josep, Albà M Mar, Bellmunt Joaquim

Abstract excerpt

Immune checkpoint inhibitors (ICI) have revolutionized cancer treatment and can result in complete remissions even at advanced stages of the disease. However, only a small fraction of patients respond to the treatment. To better understand which factors drive clinical benefit, we have generated whole exome and RNA sequencing data from 27 advanced urothelial carcinoma patients treated with anti-PD-(L)1 monoclonal...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Bladder and Urothelial Cancer Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cancer Immunotherapy and Biomarkers

Share to Carcinoma, Transitional Cell

Share to Ferroptosis and cancer prognosis

Share to Immune Checkpoint Inhibitors

Share to Mutation

Share to Urinary Bladder Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 37714872
DOI: 10.1038/s41598-023-42495-2
PMCID: PMC10504302

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The impact of mutational clonality in predicting the response to immune checkpoint inhibitors in advanced urothelial cancer.PMID 37714872Read ↗

The impact of mutational clonality in predicting the response to immune checkpoint inhibitors in advanced urothelial cancerSemantic proximity Read ↗

Contribution of systemic and somatic factors to clinical response and resistance in urothelial cancer: an exploratory multi-omic analysisSemantic proximity Read ↗

Beyond Tumor PD-L1: Emerging Genomic Biomarkers for Checkpoint Inhibitor ImmunotherapySemantic proximity Read ↗

Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current EvidenceSemantic proximity Read ↗

Is tumor mutational burden predictive of response to immunotherapy?Semantic proximity Read ↗

PD-L1 expression and tumor mutational burden are independent biomarkers in most cancersSemantic proximity Read ↗

Prognostic Value of Neoantigen Load in Immune Checkpoint Inhibitor Therapy for Cancer.Semantic proximity Read ↗

Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition.Semantic proximity Read ↗

Tumor mutational burden related classifier is predictive of response to PD-L1 blockade in locally advanced and metastatic urothelial carcinoma.Semantic proximity Read ↗

Predicting immunotherapy response in advanced bladder cancer: a meta-analysis of six independent cohortsSemantic proximity Read ↗

Whole-genome sequencing uncovers the genomic determinants of therapeutic resistance to immune checkpoint blockadeSemantic proximity Read ↗

Induced B-Cell Receptor Diversity Predicts PD-1 Blockade Immunotherapy ResponseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.